var data={"title":"Obeticholic acid: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Obeticholic acid: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/797072?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=obeticholic-acid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Obeticholic acid: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50629642\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ocaliva Safety Alert</span>\n      <span class=\"collapsible-date\">February 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">In September 2017, the FDA issued a safety alert warning that (obeticholic acid) has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis (PBC), increasing the risk of serious liver injury and death.</p>\n        <p style=\"text-indent:0em;\">To ensure correct dosing and reduce the risk of liver problems, the FDA is updating the prescribing information to clarify the current recommendations for screening, dosing, monitoring, and managing PBC patients with moderate to severe liver disease. Additionally, a Boxed Warning highlighting this information will be added to the prescribing information, and a Medication Guide will be required for patients to inform them about this issue.</p>\n        <p style=\"text-indent:0em;\">More information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm594901.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPG6jnWVdkJ4rlHSePh6VTLmOhyJ+Nznygvd8P/bvekGQX5dujULjGxVyhOXYIw1Bh9i85TeA+aP+CDg+ZuBgVnlZufDsjczQlsdBv2H3dJh0h5tM819uMtogAApmxMEUdQ==&amp;TOPIC_ID=108368\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm594901.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51129419\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatic decompensation and failure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with primary biliary cholangitis with decompensated cirrhosis or Child-Pugh class B or C hepatic impairment when obeticholic acid was dosed more frequently than recommended.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The recommended starting dose is 5 mg once weekly for patients with Child-Pugh class B or C hepatic impairment or a prior decompensation event.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742136\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ocaliva</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50795373\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ocaliva</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46679622\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Farnesoid X Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742458\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Use in combination with ursodiol (ursodeoxycholic acid) in patients with an inadequate biochemical response to treatment with an appropriate dosage of ursodiol for &ge;1 year; may be used as monotherapy in patients unable to tolerate ursodiol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary biliary cholangitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noncirrhotic or compensated Child-Pugh class A: Initial: 5 mg once daily; if an adequate reduction in alkaline phosphatase and/or total bilirubin has not been achieved after 3 months, increase to 10 mg once daily (maximum: 10 mg/day). <b>Note:</b> Prior to dose adjustment, re-calculate the Child-Pugh classification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Child-Pugh class B or C or patients with a prior decompensation event (including gastroesophageal variceal bleeding, new or worsening jaundice, spontaneous bacterial peritonitis): Initial: 5 mg once weekly; if an adequate reduction in alkaline phosphatase and/or total bilirubin has not been achieved after 3 months, increase to 5 mg twice weekly (at least 3 days apart). May titrate to 10 mg twice weekly (at least 3 days apart) based on response and tolerability (maximum: 10 mg twice weekly [at least 3 days apart]). <b>Note:</b> Prior to dose adjustment, re-calculate the Child-Pugh classification.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742459\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742460\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&prime;s labeling (has not been studied in patients with eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742461\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment prior to treatment initiation:</i> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity during treatment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Laboratory or clinical evidence of worsening liver function: Interrupt treatment and monitor liver function. If condition returns to baseline, restart treatment after weighing risks vs benefits. If treatment is re-initiated, use the recommended starting dose with adjustment for Child-Pugh classification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Significant liver-related adverse reactions: Consider discontinuing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Complete biliary obstruction: Permanently discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742462\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intolerable pruritus:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noncirrhotic or compensated cirrhotic Child-Pugh class A: Reduce dose to 5 mg every other day (for patients intolerant to 5 mg once daily) or 5 mg once daily (for patients intolerant to 10 mg once daily) or may interrupt therapy for up to 2 weeks (and restart at a reduced dose). If re-initiating therapy after dose reduction or interruption, titrate the dose based on response and tolerability and adjust according to Child-Pugh classification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Child-Pugh class B or C or patients with a prior decompensation event: Temporarily interrupt therapy for up to 2 weeks followed by reintroduction at a reduced dosage. Titrate the dose based on response and tolerability and according to Child-Pugh classification.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Persistent intolerable pruritus: Consider discontinuing therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742137\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ocaliva: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742135\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51065178\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ocaliva: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf#page=23&amp;token=AiNYxCViUNt53bF/fG7ZoYxs3NtA97rA29MJKWD1qKZH84NbLxLHVXT0V01OZ9ZcHQUIyNup1/JU5U2NTcR/IPsxblKKguKr0rtiMpWyTx/BiXgnBecZml/p0xHvKTSa&amp;TOPIC_ID=108368\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf#page=23</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742464\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with or without food. For patients taking a bile acid binding resin to manage intolerable pruritus, take obeticholic acid &ge;4 hours before or 4 hours after taking the bile acid binding resin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46679614\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Primary biliary cholangitis:</b> Treatment of primary biliary cholangitis (PBC) in combination with ursodiol (ursodeoxycholic acid) in adults with an inadequate response to ursodiol, or as monotherapy in adults unable to tolerate ursodiol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46683164\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (19% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (56% to 70%; severe: 19% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased HDL cholesterol (9% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (7%), palpitations (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (10%), eczema (3% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Thyroid dysfunction (4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (6% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Oropharyngeal pain (7% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Gastrointestinal: Cholangitis (worsening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Ascites, hepatic cirrhosis (new onset), hepatic encephalopathy (worsening), hepatic failure, hepatic insufficiency, increased direct serum bilirubin, increased serum bilirubin, jaundice (new onset and worsening), liver decompensation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46679624\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Complete biliary obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to obeticholic acid or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742446\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Dose-related hepatic adverse reactions (eg, jaundice, worsening ascites, primary biliary cholangitis [PBC] flare) have been reported in patients with primarily early stage PBC, as early as one month after initiating therapy. Monitor LFTs and for signs/symptoms of hepatic adverse reactions, especially for patients at increased risk of hepatic decompensation. Interrupt treatment in patients with laboratory or clinical evidence of worsening liver function indicating decompensation; consider discontinuation of therapy in patients who experience clinically significant liver-related adverse reactions. Permanently discontinue treatment in patients who develop complete biliary obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipid effects: Dose-dependent reductions in high density lipoprotein-cholesterol (HDL-C) levels have been reported; monitor lipids during treatment. In patients who experience a reduction in HDL-C <b>and </b>do not respond to therapy after 1 year at the maximum dosage, consider the potential risks against the benefits of continuing obeticholic acid.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pruritus: Severe pruritus (ie, intense or widespread itching, interfering with activities of daily living, or causing severe sleep disturbance or intolerable discomfort, typically requiring medical interventions) has been reported. Consider clinical evaluation for patients with new-onset or worsening severe pruritus; dosage reduction, temporary interruption of dosing, and/or addition of bile acid resins or antihistamines may be used to manage severe pruritus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic decompensation and failure: <b>[US Boxed Warning]: Hepatic decompensation and failure have been reported (including fatalities) in patients with PBC with decompensated cirrhosis or Child-Pugh class B or C hepatic impairment when obeticholic acid was dosed more frequently than the recommended starting dos</b>e. Cases were typically reported within 2 to 5 weeks after initiation of therapy and were characterized by an acute increase in total bilirubin and/or alkaline phosphatase concentrations with clinical signs and symptoms of hepatic decompensation. Some cases improved after discontinuation of therapy; patients who died due to liver-related complications generally had decompensated cirrhosis prior to treatment and were initiated on daily dosing instead of weekly dosing. Monitor patients for progression of PBC, including liver-related complications; dosage adjustment, interruption, or discontinuation may be necessary. Close monitoring is recommended for patients at increased risk of hepatic decompensation; severe intercurrent illnesses that may worsen renal function or cause dehydration (eg, gastroenteritis) may exacerbate the risk of hepatic decompensation. Monitor LFTs and interrupt treatment in patients with laboratory or clinical evidence of worsening liver function; consider discontinuation of therapy in patients who have experienced clinically significant liver-related adverse reactions. Discontinue use in patients who develop complete biliary obstruction. Dosage adjustment is recommended in patients with Child-Pugh class B and C.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46683247\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46683244\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=108368&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Obeticholic Acid. Management: Administer obeticholic acid at least 4 hours before or at least 4 hours after the administration of bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BSEP/ABCB11 Inhibitors: May increase serum concentrations of the active metabolite(s) of Obeticholic Acid. Management: Avoid concomitant use of obeticholic acid and bile salt efflux pump (BSEP) inhibitors if possible. If concomitant therapy is necessary, monitor patients for elevated liver transaminases and elevated bilirubin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inhibitors): Obeticholic Acid may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Obeticholic Acid may diminish the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742444\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742445\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if obeticholic acid is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742466\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">LFTs, including alkaline phosphatase and bilirubin, lipid profile; signs/symptoms of hepatic adverse reactions and/or pruritus; progression of PBC (laboratory and clinical assessments).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742449\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Obeticholic acid is a farnesoid X receptor agonist; activation of FXR suppresses de novo synthesis of bile acids from cholesterol and increases transport of bile acids out of the hepatocytes, limiting the overall size of the circulating bile acid pool while promoting choleresis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742451\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 618 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Conjugated in the liver to active metabolites (glyco- and tauro- obeticholic acid; activity similar to parent drug) that undergo enterohepatic recirculation and conversion by intestinal microbiota back to obeticholic acid that is reabsorbed or excreted. A third metabolite, 3-glucuronide, has minimal pharmacologic activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Obeticholic acid: ~1.5 hours; glyco- and tauro- obeticholic acid: 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~87%); urine (&lt;3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46817120\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ocaliva Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $7,353.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $7,353.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49940165\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ocaliva (AT, CZ, DE, DK, EE, FR, HR, LT, LV, NO, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Ocaliva (obeticholic acid): Drug Safety Communication - Increased Risk of Serious Liver Injury. Food and Drug Administration website. Available at <a href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm576861.htm\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm576861.htm</a>. Accessed September 27, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals, Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ocaliva (obeticholic acid) [product monograph]. Vancouver, BC, Canada: Intercept Pharmaceuticals, Inc; May 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 108368 Version 30.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50629642\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F51129419\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46742136\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50795373\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46679622\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46742458\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46742459\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46742460\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46742461\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F46742462\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46742137\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46742135\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F51065178\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46742464\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46679614\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46683164\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46679624\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46742446\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46683247\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46683244\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46742444\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46742445\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46742466\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46742449\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46742451\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46817120\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49940165\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/108368|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=obeticholic-acid-patient-drug-information\" class=\"drug drug_patient\">Obeticholic acid: Patient drug information</a></li></ul></div></div>","javascript":null}